Sex-driven modifiers of Alzheimer risk A multimodality brain imaging study
- 23 June 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 95 (2), E166-E178
- https://doi.org/10.1212/WNL.0000000000009781
Abstract
Objective To investigate sex differences in late-onset Alzheimer disease (AD) risks by means of multimodality brain biomarkers (beta-amyloid load via(11)C-Pittsburgh compound B [PiB] PET, neurodegeneration via(18)F-fluorodeoxyglucose [FDG] PET and structural MRI). Methods We examined 121 cognitively normal participants (85 women and 36 men) 40 to 65 years of age with clinical, laboratory, neuropsychological, lifestyle, MRI, FDG- and PiB-PET examinations. Several clinical (e.g., age, education,APOEstatus, family history), medical (e.g., depression, diabetes mellitus, hyperlipidemia), hormonal (e.g., thyroid disease, menopause), and lifestyle AD risk factors (e.g., smoking, diet, exercise, intellectual activity) were assessed. Statistical parametric mapping and least absolute shrinkage and selection operator regressions were used to compare AD biomarkers between men and women and to identify the risk factors associated with sex-related differences. Results Groups were comparable on clinical and cognitive measures. After adjustment for each modality-specific confounders, the female group showed higher PiB beta-amyloid deposition, lower FDG glucose metabolism, and lower MRI gray and white matter volumes compared to the male group (p< 0.05, family-wise error corrected for multiple comparisons). The male group did not show biomarker abnormalities compared to the female group. Results were independent of age and remained significant with the use of age-matched groups. Second to female sex, menopausal status was the predictor most consistently and strongly associated with the observed brain biomarker differences, followed by hormone therapy, hysterectomy status, and thyroid disease. Conclusion Hormonal risk factors, in particular menopause, predict AD endophenotype in middle-aged women. These findings suggest that the window of opportunity for AD preventive interventions in women is early in the endocrine aging process.This publication has 40 references indexed in Scilit:
- Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differencesClinical Epidemiology, 2014
- Preclinical Alzheimer disease—the challenges aheadNature Reviews Neurology, 2012
- Executive summary of the Stages of Reproductive Aging Workshop + 10Menopause, 2012
- The projected effect of risk factor reduction on Alzheimer's disease prevalenceThe Lancet Neurology, 2011
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopauseNeurology, 2007
- Assessment of Lifetime Participation in Cognitively Stimulating ActivitiesJournal of Clinical and Experimental Neuropsychology, 2003
- Voxel-Based Morphometry—The MethodsNeuroImage, 2000
- Thyroid Hormone Negatively Regulates the Transcriptional Activity of the β-Amyloid Precursor Protein GeneOnline Journal of Public Health Informatics, 1998
- A questionnaire for the assessment of leisure time physical activitiesJournal of Chronic Diseases, 1978